Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Private equity firm CD&R and healthcare giant McKesson are acquiring Option Care Health — the country's largest independent at-home infusion services provider — for $5.8 billion. The deal takes Option Care private at $32.05 per share, a 37% premium, and is expected to close in the first half of 2027. McKesson sees the move as a strategic play to expand specialty care delivery in lower-cost, non-traditional settings.
Private equity firm CD&R and healthcare conglomerate McKesson are joining forces to acquire Option Care Health in a $5.8 billion deal announced Tuesday. The transaction will take Option Care private at $32.05 per share — a 37% premium over its recent closing price — with CD&R holding a 51% stake and McKesson investing roughly $1.4 billion for a ~49% interest. The deal is expected to close in the first half of 2027, pending regulatory and shareholder approvals.
Option Care Health operates across all 50 states, serving more than 308,000 patients annually with a workforce of 8,000 — 5,000 of whom are clinicians. McKesson framed the acquisition as a natural extension of its specialty care strategy, citing growing demand for complex therapies — including rare and orphan drugs — that increasingly require alternate-site infusion delivery.
By the Numbers:
Why it matters: This deal signals a major consolidation in the home and alternate-site infusion space, with implications for how complex therapies reach patients outside hospital walls. As specialty drug pipelines grow, controlling the infusion delivery infrastructure becomes a significant strategic — and financial — advantage.
